Digital integration enables financiers to assess eligibility, obtain guarantee cover and complete the guarantee process on the TReDS platfo...

As an investor, what you need to do at this point of time is this: A bit of extra work in terms of stock-picking so that you avoid anxiety ...

With the US market shedding weight overnight, the probability is high that Thursday will see another day of choppy trading. The best way to...

PGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...

Geopolitical tensions, tariff uncertainty and repeated supply-chain disruptions are pushing global companies to move from periodic procurem...

The number of enterprises in the formal ecosystem has increased from around 16.5 million three to four years ago to 92 million currently, s...

Happy Friday! We are excited to bring to you the 12th edition of The Economic Times Startup Awards (ETSA). A few days before our esteemed j...

Shiprocket’s strong stock market debut reflects surging investor confidence in India’s tech-driven e-commerce infrastructure. As rapid D2C ...

For the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

GeM's Womaniya initiative has empowered over 200,000 women entrepreneurs in public procurement. This program has dismantled barriers, enabl...

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

Indian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's ...

The measure is expected to boost availability of the drug that’s being used for Covid treatment. Supplies of the drug have been running low...

Over a two-three-year period, the pricing power in API space will ebb away and margins will come back down, says Saurabh Mukherjea.

India, the world’s third-largest drug producer by volumes, imports 70% of its APIs from China. For some APIs, especially antibiotics, depen...